PannTheraPi is the first pharmaceutical company dedicated to the development of Pannexin 1 channel blocker drugs for the treatment of brain and nervous diseases, aiming for better efficacy and better tolerance than current drugs. PannTheraPi offers breakthrough innovation for the two main issues in development of current drugs in neurological diseases: - Innovative target adressing the root cause of the diseases - Representative non-clinical model using human brain tissues PanTheraPi generates repurposed and new chemical entities drugs.